Chemokines and their receptors: Potential therapeutic targets for bone cancer pain

Current Pharmaceutical Design

Volumn 21, Issue 34, 2015, Pages 5029-5033

  Zhou, Ya Qun ^a   Gao, Heng Yi ^a   Guan, Xue Hai ^a   Yuan, Xun ^a   Fang, Guang Guang ^b   Chen, Yuan ^a   Ye, Da Wei ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SHENZHEN UNIVERSITY   (China)

Author keywords

Bone cancer pain; Chemokine; Chemokine receptor; Therapeutic target

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; ANALGESIC AGENT;

ALLODYNIA; ARTICLE; BONE CANCER; CANCER PAIN; HUMAN; HYPERALGESIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; ANIMAL; BONE TUMOR; COMPLICATION; DRUG DESIGN; METABOLISM; MOLECULARLY TARGETED THERAPY; PAIN; PATHOPHYSIOLOGY;

ANALGESICS; ANIMALS; BONE NEOPLASMS; CHEMOKINES; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; PAIN; RECEPTORS, CHEMOKINE;

EID: 84947969731     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150831141931     Document Type: Article

References (64)

1. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006; 12: 6243s-9s.
2. Yeh DC, Chen DR, Chao TY, et al. EORTC QLQ-BM22 quality of life evaluation and pain outcome in patients with bone metastases from breast cancer treated with zoledronic acid. In Vivo 2014; 28: 1001-4.
3. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997; 69:1-18.
4. Mercadante S, Arcuri E. Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev 1998; 24: 425- 32.
5. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990; 41: 273-81.
6. Laird BJ, Walley J, Murray GD, Clausen E, Colvin LA, Fallon MT. Characterization of cancer-induced bone pain: an exploratory study. Support Care Cancer 2011; 19: 1393-401.
7. Holzer P, Ahmedzai SH, Niederle N, et al. Opioid-induced bowel dysfunction in cancer-related pain: causes, consequences, and a novel approach for its management. J Opioid Manag 2009; 5: 145- 51.
8. Flemming K. The use of morphine to treat cancer-related pain: a synthesis of quantitative and qualitative research. J Pain Symptom Manage 2010; 39: 139-54.
9. Knerlich-Lukoschus F, von der Ropp-Brenner B, Lucius R, Mehdorn HM, Held-Feindt J. Spatiotemporal CCR1, CCL3(MIP- 1alpha), CXCR4, CXCL12(SDF-1alpha) expression patterns in a rat spinal cord injury model of posttraumatic neuropathic pain. J Neurosurg Spine 2011; 14: 583-97.
10. Saika F, Kiguchi N, Kobayashi Y, Fukazawa Y, Kishioka S. CCchemokine ligand 4/macrophage inflammatory protein-1beta participates in the induction of neuropathic pain after peripheral nerve injury. Eur J Pain 2012; 16: 1271-80.
11. Zhang ZJ, Cao DL, Zhang X, Ji RR, Gao YJ. Chemokine contribution to neuropathic pain: respective induction of CXCL1 and CXCR2 in spinal cord astrocytes and neurons. Pain 2013; 154: 2185-97.
12. Clark AK, Malcangio M. Fractalkine/CX3CR1 signaling during neuropathic pain. Front Cell Neurosci 2014; 8: 121.
13. Van Steenwinckel J, Auvynet C, Sapienza A, Reaux-Le Goazigo A, Combadiere C, Melik Parsadaniantz S. Stromal cell-derived CCL2 drives neuropathic pain states through myeloid cell infiltration in injured nerve. Brain Behav Immun 2015; 45: 198-210.
14. Pienta KJ, Machiels JP, Schrijvers D, et al. Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CCchemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. Invest New Drugs 2013; 31: 760-8.
15. Hsu YL, Hou MF, Kuo PL, Huang YF, Tsai EM. Breast tumorassociated osteoblast-derived CXCL5 increases cancer progression by ERK/MSK1/Elk-1/snail signaling pathway. Oncogene 2013; 32: 4436-47.
16. Fetterly GJ, Aras U, Meholick PD, et al. Utilizing pharmacokinetics/ pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data. J Clin Pharmacol 2013; 53: 1020-7.
17. Zhang P, Dong L, Yan K, et al. CXCR4-mediated osteosarcoma growth and pulmonary metastasis is promoted by mesenchymal stem cells through VEGF. Oncol Rep 2013; 30: 1753-61.
18. Ding X, Yang DR, Lee SO, et al. TR4 nuclear receptor promotes prostate cancer metastasis via upregulation of CCL2/CCR2 signaling. Int J Cancer 2015; 136: 955-64.
19. Schiller KR, Zillhardt MR, Alley J, Borjesson DL, Beitz AJ, Mauro LJ. Secretion of MCP-1 and other paracrine factors in a novel tumor- bone coculture model. BMC Cancer 2009; 9: 45.
20. Kominsky SL, Abdelmagid SM, Doucet M, Brady K, Weber KL. Macrophage inflammatory protein-1 delta: a novel osteoclast stimulating factor secreted by renal cell carcinoma bone metastasis. Cancer Res 2008; 68: 1261-6.
21. Lee YS, Choi I, Ning Y, et al. Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis. Br J Cancer 2012; 106: 1833- 41.
22. Zhou SL, Dai Z, Zhou ZJ, et al. CXCL5 contributes to tumor metastasis and recurrence of intrahepatic cholangiocarcinoma by recruiting infiltrative intratumoral neutrophils. Carcinogenesis 2014; 35: 597-605.
23. Bajetto A, Bonavia R, Barbero S, Schettini G. Characterization of chemokines and their receptors in the central nervous system: physiopathological implications. J Neurochem 2002; 82: 1311-29.
24. Kim CH. Chemokine-chemokine receptor network in immune cell trafficking. Curr Drug Targets Immune Endocr Metabol Disord 2004; 4: 343-61.
25. Ransohoff RM. Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology. Immunity 2009; 31: 711-21.
26. Bacon K, Baggiolini M, Broxmeyer H, et al. Chemokine/ chemokine receptor nomenclature. J Interferon Cytokine Res 2002; 22: 1067-8.
27. Murphy PM, Baggiolini M, Charo IF, et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000; 52: 145-76.
28. Franciszkiewicz K, Boissonnas A, Boutet M, Combadiere C, Mami-Chouaib F. Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response. Cancer Res 2012; 72: 6325-32.
29. Lazennec G, Richmond A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med 2010; 16: 133-44.
30. Roy I, Evans DB, Dwinell MB. Chemokines and chemokine receptors: update on utility and challenges for the clinician. Surgery 2014; 155: 961-73.
31. White FA, Wilson NM. Chemokines as pain mediators and modulators. Curr Opin Anaesthesiol 2008; 21: 580-5.
32. White FA, Jung H, Miller RJ. Chemokines and the pathophysiology of neuropathic pain. Proc Natl Acad Sci USA 2007; 104: 20151-8.
33. Van Coillie E, Van Damme J, Opdenakker G. The MCP/eotaxin subfamily of CC chemokines. Cytokine Growth Factor Rev 1999; 10: 61-86.
34. Hu JH, Zheng XY, Yang JP, Wang LN, Ji FH. Involvement of spinal monocyte chemoattractant protein-1 (MCP-1) in cancerinduced bone pain in rats. Neurosci Lett 2012; 517: 60-63.
35. Jin D, Yang JP, Hu JH, Wang LN, Zuo JL. MCP-1 stimulates spinal microglia via PI3K/Akt pathway in bone cancer pain. Brain Res 2015; 1599: 158-67.
36. Pevida M, Gonzalez-Rodriguez S, Lastra A, et al. Involvement of spinal chemokine CCL2 in the hyperalgesia evoked by bone cancer in mice: a role for astroglia and microglia. Cell Mol Neurobiol 2014; 34: 143-56.
37. Suffee N, Hlawaty H, Meddahi-Pelle A, et al. RANTES/CCL5- induced pro-angiogenic effects depend on CCR1, CCR5 and glycosaminoglycans. Angiogenesis 2012; 15: 727-44.
38. Padi SS, Shi XQ, Zhao YQ, et al. Attenuation of rodent neuropathic pain by an orally active peptide, RAP-103, which potently blocks CCR2- and CCR5-mediated monocyte chemotaxis and inflammation. Pain 2012; 153: 95-106.
39. Yin Q, Fan Q, Zhao Y, et al. Spinal NF-kappaB and chemokine ligand 5 expression during spinal glial cell activation in a neuropathic pain model. PLoS One 2015; 10: e0115120.
40. Liou JT, Yuan HB, Mao CC, Lai YS, Day YJ. Absence of C-C motif chemokine ligand 5 in mice leads to decreased local macrophage recruitment and behavioral hypersensitivity in a murine neuropathic pain model. Pain 2012; 153: 1283-91.
41. Liou JT, Mao CC, Ching-Wah Sum D, et al. Peritoneal administration of Met-RANTES attenuates inflammatory and nociceptive responses in a murine neuropathic pain model. J Pain 2013; 14: 24- 35.
42. Hang LH, Shao DH, Chen Z, et al. Involvement of spinal CC chemokine ligand 5 in the development of bone cancer pain in rats. Basic Clin Pharmacol Toxicol 2013; 113: 325-8.
43. Hang LH, Li SN, Shao DH, et al. Evidence for involvement of spinal RANTES in the antinociceptive effects of triptolide, a diterpene triepoxide, in a rat model of bone cancer pain. Basic Clin Pharmacol Toxicol 2014; 115: 477-80.
44. Bazan JF, Bacon KB, Hardiman G, et al. A new class of membrane- bound chemokine with a CX3C motif. Nature 1997; 385: 640-4.
45. Yin Q, Cheng W, Cheng MY, Fan SZ, Shen W. Intrathecal injection of anti-CX3CR1 neutralizing antibody delayed and attenuated pain facilitation in rat tibial bone cancer pain model. Behav Pharmacol 2010; 21: 595-601.
46. Hu JH, Yang JP, Liu L, et al. Involvement of CX3CR1 in bone cancer pain through the activation of microglia p38 MAPK pathway in the spinal cord. Brain Res 2012; 1465: 1-9.
47. Salcedo R, Oppenheim JJ. Role of chemokines in angiogenesis: CXCL12/SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses. Microcirculation 2003; 10: 359-70.
48. Li M, Ransohoff RM. Multiple roles of chemokine CXCL12 in the central nervous system: a migration from immunology to neurobiology. Prog Neurobiol 2008; 84: 116-31.
49. Shen W, Hu XM, Liu YN, et al. CXCL12 in astrocytes contributes to bone cancer pain through CXCR4-mediated neuronal sensitization and glial activation in rat spinal cord. J Neuroinflammation 2014; 11: 75.
50. Hu XM, Liu YN, Zhang HL, et al. CXCL12/CXCR4 chemokine signaling in spinal glia induces pain hypersensitivity through MAPKs-mediated neuroinflammation in bone cancer rats. J Neurochem 2015; 132: 452-63.
51. Bu H, Shu B, Gao F, et al. Spinal IFN-gamma-induced protein-10 (CXCL10) mediates metastatic breast cancer-induced bone pain by activation of microglia in rat models. Breast Cancer Res Treat 2014; 143: 255-63.
52. Ye D, Bu H, Guo G, et al. Activation of CXCL10/CXCR3 signaling attenuates morphine analgesia: involvement of Gi protein. J Mol Neurosci 2014; 53: 571-9.
53. Guan XH, Fu QC, Shi D, et al. Activation of spinal chemokine receptor CXCR3 mediates bone cancer pain through an Akt-ERK crosstalk pathway in rats. Exp Neurol 2015; 263: 39-49.
54. Guo G, Gao F. CXCR3: latest evidence for the involvement of chemokine signaling in bone cancer pain. Exp Neurol 2015; 265: 176-9.
55. Xu J, Zhu MD, Zhang X, et al. NFkappaB-mediated CXCL1 production in spinal cord astrocytes contributes to the maintenance of bone cancer pain in mice. J Neuroinflammation 2014; 11: 38.
56. Zhu X, Cao S, Zhu MD, Liu JQ, Chen JJ, Gao YJ. Contribution of chemokine CCL2/CCR2 signaling in the dorsal root ganglion and spinal cord to the maintenance of neuropathic pain in a rat model of lumbar disc herniation. J Pain 2014; 15: 516-26.
57. Zhu W, Acosta C, MacNeil B, et al. Elevated expression of fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) in the dorsal root ganglia and spinal cord in experimental autoimmune encephalomyelitis: implications in multiple sclerosis-induced neuropathic pain. Biomed Res Int 2013; 480: 702.
58. Kiguchi N, Kobayashi Y, Maeda T, et al. Epigenetic augmentation of the macrophage inflammatory protein 2/C-X-C chemokine receptor type 2 axis through histone H3 acetylation in injured peripheral nerves elicits neuropathic pain. J Pharmacol Exp Ther 2012; 340: 577-87.
59. Biber K, Tsuda M, Tozaki-Saitoh H, et al. Neuronal CCL21 upregulates microglia P2X4 expression and initiates neuropathic pain development. EMBO J 2011; 30: 1864-73.
60. Kiguchi N, Kobayashi Y, Maeda T, Saika F, Kishioka S. CCchemokine MIP-1alpha in the spinal cord contributes to nerve injury- induced neuropathic pain. Neurosci Lett 2010; 484: 17-21.
61. Gao YJ, Zhang L, Samad OA, et al. JNK-induced MCP-1 production in spinal cord astrocytes contributes to central sensitization and neuropathic pain. J Neurosci 2009; 29: 4096-108.
62. Lazaar AL, Sweeney LE, MacDonald AJ, Alexis NE, Chen C, Tal- Singer R. SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. Br J Clin Pharmacol 2011; 72: 282-93.
63. Virtala R, Ekman AK, Jansson L, Westin U, Cardell LO. Airway inflammation evaluated in a human nasal lipopolysaccharide challenge model by investigating the effect of a CXCR2 inhibitor. Clin Exp Allergy 2012; 42: 590-6.
64. Holz O, Khalilieh S, Ludwig-Sengpiel A, et al. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. Eur Respir J 2010; 35: 564-70.